The Rare Diseases Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Home-based Care Anticipated to Offer Lucrative Growth Prospects
There are unmet requirements for elderly, frail people with multiple diseases, but many support services today focus on patients with rare or ultra-rare diseases. In addition, there are numerous chronic conditions present in sizable patient communities, even in younger age groups. Expanding home-based healthcare services could therefore have positive effects on bigger patient populations and health systems.
Due to the high degrees of medical complexity, managing comorbidities and multi-morbidities is especially difficult. A patient with heart failure who also requires infusion therapy for cancer poses a problem with timing the administration of the diuretics because the patient must travel to the infusion facility. Home-based care services may develop into a potent catalyst for raising standards of care, enhancing patient satisfaction, and cutting expenses. While there are obvious and distinct benefits for patients and carers with complex and rare diseases, there are also advantages for larger patient populations with more widespread conditions who may face difficulties due to the complexity of their therapy or the effects of comorbidities and multidisease.
What Questions Should You Ask before Buying a Market Research Report?
• How is the rare diseases market evolving?
• What is driving and restraining the rare diseases market?
• How will each rare diseases submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each rare diseases submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading rare diseases markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the rare diseases projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
rare diseases projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the rare diseases market?
• Where is the rare diseases market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the rare diseases market today, and over the next 10 years:
• Our 290-page report provides 107 tables and 186 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the rare diseases market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Diseases
• Cancer
• Metabolic Diseases
• Neurological Conditions
• Hematologic Disorders
• Infectious Diseases
• Musculoskeletal Disorders
• Cardiovascular Disorders
• Others
Type
• Non-biologics
• Biologics
End-users
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
Age
• Adult
• Paediatric
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Rare Diseases Market, 2023 to 2033, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie Inc.
• Alexion Pharmaceuticals, Inc. (AstraZeneca)
• Amgen Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Merck & Co Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
Overall world revenue for Rare Diseases Market, 2023 to 2033 in terms of value the market will surpass US$205.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Rare Diseases Market, 2023 to 2033 report help you?
In summary, our 290-page report provides you with the following knowledge:
• Revenue forecasts to 2033 for Rare Diseases Market, 2023 to 2033 Market, with forecasts for diseases, type, end-users, and age, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 21 key national markets – See forecasts for the Rare Diseases Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the Rare Diseases Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Rare Diseases Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
'
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Rare Diseases Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Number of Approval Driving Market Growth
3.2.1.2 Robust Pipeline by Major Players
3.2.1.2.1 Pfizer Rare Disease Pipeline
3.2.1.2.2 Sanofi Genzyme Corporation Rare Disease Pipeline
3.2.1.2.3 Novo Nordisk Rare Disease Pipeline
3.2.1.3 Increasing Awareness
3.2.2 Market Restraining Factors
3.2.2.1 High Research and Development Costs
3.2.2.2 High Entry Barriers to Challenge Market Growth
3.2.2.3 Physical Management of Patients Likely to Challenge Market Growth
3.2.3 Market Opportunities
3.2.3.1 Increasing Demand from Emerging Economies
3.2.3.2 Home-based Care Anticipated to Offer Lucrative Growth Prospects
3.2.3.3 Increasing Government Support
3.2.3.4 Rare Diseases Clinical Activity by Indication
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Buyers (Low)
3.4.2 Bargaining Power of Suppliers (medium)
3.4.3 Threat of Substitutes (Low)
3.4.4 Threat of New Entrants (Low)
3.4.5 Industry Rivalry (High)
4 Rare Diseases Market Analysis by Diseases
4.1 Key Findings
4.2 Diseases Segment: Market Attractiveness Index
4.3 Rare Diseases Market Size Estimation and Forecast by Diseases
4.4 Cancer
4.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Metabolic Diseases
4.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Neurological Conditions
4.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Hematologic Disorders
4.7.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Infectious Diseases
4.8.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.8.2 Market Share by Region, 2023 & 2033 (%)
4.9 Musculoskeletal Disorders
4.9.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.9.2 Market Share by Region, 2023 & 2033 (%)
4.10 Cardiovascular Disorders
4.10.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.10.2 Market Share by Region, 2023 & 2033 (%)
4.11 Others
4.11.1 Market Forecast by Region, 2023-2033 (US$ bn)
4.11.2 Market Share by Region, 2023 & 2033 (%)
5 Rare Diseases Market Analysis by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Rare Diseases Market Size Estimation and Forecast by Type
5.4 Non-biologics
5.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Biologics
5.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
5.5.2 Market Share by Region, 2023 & 2033 (%)
6 Rare Diseases Market Analysis by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Rare Diseases Market Size Estimation and Forecast by End-users
6.4 Specialty Pharmacies
6.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Hospital Pharmacies
6.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Retail Pharmacies
6.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
6.6.2 Market Share by Region, 2023 & 2033 (%)
7 Rare Diseases Market Analysis by Age
7.1 Key Findings
7.2 Age Segment: Market Attractiveness Index
7.3 Rare Diseases Market Size Estimation and Forecast by Age
7.4 Adult
7.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 Pediatric
7.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
7.5.2 Market Share by Region, 2023 & 2033 (%)
8 Rare Diseases Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Rare Diseases Market Analysis
9.1 Key Findings
9.2 North America Rare Diseases Market Attractiveness Index
9.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
9.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
9.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
9.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
9.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
9.9 U.S. Rare Diseases Market Analysis
9.10 Canada Rare Diseases Market Analysis
10 Europe Rare Diseases Market Analysis
10.1 Key Findings
10.2 Europe Rare Diseases Market Attractiveness Index
10.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
10.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
10.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
10.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
10.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
10.9 Germany Rare Diseases Market Analysis
10.10 UK Rare Diseases Market Analysis
10.11 France Rare Diseases Market Analysis
10.12 Italy Rare Diseases Market Analysis
10.13 Spain Rare Diseases Market Analysis
10.14 Russia Rare Diseases Market Analysis
10.15 Rest of Europe Rare Diseases Market Analysis
11 Asia Pacific Rare Diseases Market Analysis
11.1 Key Findings
11.2 Asia Pacific Rare Diseases Market Attractiveness Index
11.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
11.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
11.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
11.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
11.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
11.9 Japan Rare Diseases Market Analysis
11.10 China Rare Diseases Market Analysis
11.11 India Rare Diseases Market Analysis
11.12 Australia Rare Diseases Market Analysis
11.13 South Korea Rare Diseases Market Analysis
11.14 Rest of Asia Pacific Rare Diseases Market Analysis
12 Latin America Rare Diseases Market Analysis
12.1 Key Findings
12.2 Latin America Rare Diseases Market Attractiveness Index
12.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
12.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
12.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
12.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
12.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
12.9 Brazil Rare Diseases Market Analysis
12.10 Mexico Rare Diseases Market Analysis
12.11 Rest of Latin America Rare Diseases Market Analysis
13 MEA Rare Diseases Market Analysis
13.1 Key Findings
13.2 MEA Rare Diseases Market Attractiveness Index
13.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
13.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
13.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
13.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
13.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
13.9 GCC Rare Diseases Market Analysis
13.10 South Africa Rare Diseases Market Analysis
13.11 Rest of MEA Rare Diseases Market Analysis
14 Company Profiles
14.1 AbbVie Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Financial Analysis
14.1.3.1 Net Revenue, 2015-2022
14.1.3.2 Regional Market Shares, 2021
14.1.3.3 Gross Profit, 2015-2022
14.1.3.4 R&D, 2015-2022
14.1.4 Product Benchmarking
14.2 Alexion Pharmaceuticals, Inc. (AstraZeneca)
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.2.4 Strategic Outlook
14.3 Amgen Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2022
14.3.3.2 Regional Market Shares, 2022
14.3.3.3 Gross Profit, 2015-2022
14.3.3.4 R&D, 2015-2022
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Biogen Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2015-2021
14.4.3.2 Gross Profit, 2015-2021
14.4.3.3 R&D, 2015-2021
14.4.4 Product Benchmarking
14.4.5 Strategic Outlook
14.5 F. Hoffmann-La Roche Ltd.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2015-2021
14.5.3.2 Gross Profit, 2015-2021
14.5.3.3 R&D, 2015-2021
14.5.4 Product Benchmarking
14.5.5 Strategic Outlook
14.6 Johnson & Johnson Services, Inc.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2015-2022
14.6.3.2 Regional Market Shares, 2021
14.6.3.3 Gross Profit, 2015-2022
14.6.3.4 R&D, 2015-2022
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Merck & Co Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2015-2022
14.7.3.2 Regional Market Shares, 2021
14.7.3.3 Gross Profit, 2015-2022
14.7.3.4 R&D, 2015-2022
14.7.4 Product Benchmarking
14.8 Novartis AG
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2015-2022
14.8.3.2 Regional Market Shares, 2021
14.8.3.3 Gross Profit, 2015-2022
14.8.3.4 R&D, 2015-2022
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Pfizer Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2015-2022
14.9.3.2 Regional Market Shares, 2021
14.9.3.3 Gross Profit, 2015-2022
14.9.3.4 R&D, 2015-2022
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 Sanofi S.A.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2015-2022
14.10.3.2 Regional Market Shares, 2021
14.10.3.3 Gross Profit, 2015-2022
14.10.3.4 R&D, 2015-2022
14.10.4 Product Benchmarking
14.11 Takeda Pharmaceuticals
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2015-2022
14.11.3.2 Gross Profit, 2015-2022
14.11.3.3 R&D, 2015-2022
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Teva Pharmaceuticals
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2015-2021
14.12.3.2 Regional Market Shares, 2021
14.12.3.3 Gross Profit, 2015-2021
14.12.3.4 R&D, 2015-2021
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Bristol-Myers Squibb Company
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2015-2022
14.13.3.2 Gross Profit, 2015-2022
14.13.3.3 R&D, 2015-2022
14.13.4 Product Benchmarking
14.13.5 Strategic Outlook
15 Conclusion and Recommendations
15.1 Concluding Remarks
15.2 Recommendations for Market Players
List of Tables
Table 1 Prevalence Criteria Used by Regulatory Agencies to Define Rare Diseases
Table 2 Rare Diseases Market Snapshot, 2023 & 2033 (US$ billion, CAGR %)
Table 3 Rare Diseases Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 4 Rare Diseases Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 5 Rare Diseases Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 6 Rare Diseases Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 7 Key Factors Affecting the Bargaining Power of Buyer
Table 8 Key Factors Affecting the Bargaining Power of Suppliers
Table 9 Key Factors Affecting the Threat of Substitutes
Table 10 Key Factors Affecting the Threat of New Entrants
Table 11 Key Factors Affecting the Industry Rivalry
Table 12 Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 13 Cancer Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 14 Metabolic Diseases Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 15 Neurological Conditions Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 16 Hematologic Disorders Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 17 Infectious Diseases Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 18 Musculoskeletal Disorders Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 19 Cardiovascular Disorders Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 20 Others Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 21 Rare Diseases Market Forecast by Type, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 22 Non-biologics Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 23 Biologics Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 24 Rare Diseases Market Forecast by End-use, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 25 Specialty Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 26 Hospital Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 27 Retail Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 28 Rare Diseases Market Forecast by End-user, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 29 Adult Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 30 Pediatric Segment Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 31 Rare Diseases Market Forecast by Region, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 32 North America Rare Diseases Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 33 North America Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 34 North America Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 35 North America Rare Diseases Market Forecast by End-use, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 36 North America Rare Diseases Market Forecast by Age, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 37 U.S. Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 38 Canada Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 39 Europe Rare Diseases Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 40 Europe Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 41 Europe Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 42 Europe Rare Diseases Market Forecast by End-use, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 43 Europe Rare Diseases Market Forecast by Age, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 44 Germany Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 45 UK Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 46 France Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 47 Italy Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 48 Spain Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 49 Russia Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 50 Rest of Europe Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 51 Asia Pacific Rare Diseases Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 52 Asia Pacific Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 53 Asia Pacific Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 54 Asia Pacific Rare Diseases Market Forecast by End-use, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 55 Asia Pacific Rare Diseases Market Forecast by Age, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 56 Japan Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 57 China Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 58 India Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 59 Australia Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 60 South Korea Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 61 Rest of Asia Pacific Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 62 Latin America Rare Diseases Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 63 Latin America Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 64 Latin America Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 65 Latin America Rare Diseases Market Forecast by End-use, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 66 Latin America Rare Diseases Market Forecast by Age, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 67 Brazil Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 68 Mexico Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 69 Rest of Latin America Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 70 MEA Rare Diseases Market Forecast by Country, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 71 MEA Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 72 MEA Rare Diseases Market Forecast by Disease, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 73 MEA Rare Diseases Market Forecast by End-use, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 74 MEA Rare Diseases Market Forecast by Age, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 75 GCC Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 76 South Africa Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 77 Rest of MEA Rare Diseases Market Forecast, 2023-2033 (US$ bn, AGR%, CAGR%)
Table 78 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 AbbVie Inc.: Product Benchmarking
Table 80 Alexion Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Alexion Pharmaceuticals, Inc.: Product Benchmarking
Table 82 Alexion Pharmaceuticals, Inc.: Strategic Outlook
Table 83 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Amgen Inc.: Product Benchmarking
Table 85 Amgen Inc.: Strategic Outlook
Table 86 Biogen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Biogen Inc.: Product Benchmarking
Table 88 Biogen Inc.: Strategic Outlook
Table 89 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 F. Hoffmann-La Roche Ltd.: Product Benchmarking
Table 91 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 92 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Johnson & Johnson Services, Inc.: Product Benchmarking
Table 94 Johnson & Johnson Services, Inc.: Strategic Outlook
Table 95 Merck & Co Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Merck & Co Inc.: Product Benchmarking
Table 97 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Novartis AG: Product Benchmarking
Table 99 Novartis AG: Strategic Outlook
Table 100 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Pfizer Inc.: Product Benchmarking
Table 102 Pfizer Inc.: Strategic Outlook
Table 103 Sanofi S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Sanofi S.A.: Product Benchmarking
Table 105 Takeda Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Takeda Pharmaceuticals: Product Benchmarking
Table 107 Takeda Pharmaceuticals: Strategic Outlook
Table 108 Teva Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Teva Pharmaceuticals: Product Benchmarking
Table 110 Teva Pharmaceuticals: Strategic Outlook
Table 111 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Bristol-Myers Squibb Company: Product Benchmarking
Table 113 Bristol-Myers Squibb Company: Strategic Outlook
List of Figures
Figure 1 Rare Diseases Market Segmentation
Figure 2 Rare Diseases Market by Diseases: Market Attractiveness Index
Figure 3 Rare Diseases Market by Type: Market Attractiveness Index
Figure 4 Rare Diseases Market by End-users: Market Attractiveness Index
Figure 5 Rare Diseases Market by Age: Market Attractiveness Index
Figure 6 Rare Diseases Market Attractiveness Index by Region
Figure 7 Rare Diseases Market: Market Dynamics
Figure 8 CDER’s Annual Novel Drug Approvals: 2011 – 2022
Figure 9 Rare Diseases Clinical Activity by Indication
Figure 10 Rare Diseases Clinical Activity by Indication
Figure 11 Rare versus Prevalent Diseases Clinical Trials by Phase
Figure 12 Rare Diseases Market by Region, 2023-2033 (US$ bn, AGR %): “V” Shaped Recovery
Figure 13 Rare Diseases Market by Region, 2023-2033 (US$ bn, AGR %): “U” Shaped Recovery
Figure 14 Rare Diseases Market by Region, 2023-2033 (US$ bn, AGR %): “W” Shaped Recovery
Figure 15 Rare Diseases Market by Region, 2023-2033 (US$ bn, AGR %): “L” Shaped Recovery
Figure 16 Global Rare Disease Market: Porter’s Five Forces Analysis
Figure 17 Rare Diseases Market Attractiveness Index by Diseases
Figure 18 Rare Diseases Market Forecast by Diseases, 2023-2033 (US$ billion)
Figure 19 Rare Diseases Market Share Forecast by Diseases, 2023, 2028, 2033 (%)
Figure 20 Cancer Market Forecast by Region, 2023-2033 (US$ billion)
Figure 21 Cancer Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Metabolic Diseases Market Forecast by Region, 2023-2033 (US$ billion)
Figure 23 Metabolic Diseases Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Neurological Conditions Market Forecast by Region, 2023-2033 (US$ billion)
Figure 25 Neurological Conditions Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Hematologic Disorders Market Forecast by Region, 2023-2033 (US$ billion)
Figure 27 Hematologic Disorders Market Share Forecast by Region, 2023 & 2033 (%)
Figure 28 Infectious Diseases Market Forecast by Region, 2023-2033 (US$ billion)
Figure 29 Infectious Diseases Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Musculoskeletal Disorders Market Forecast by Region, 2023-2033 (US$ billion)
Figure 31 Musculoskeletal Disorders Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Cardiovascular Disorders Market Forecast by Region, 2023-2033 (US$ billion)
Figure 33 Cardiovascular Disorders Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Others Market Forecast by Region, 2023-2033 (US$ billion)
Figure 35 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 36 Rare Diseases Market Attractiveness Index by Diseases
Figure 37 Rare Diseases Market Forecast by Type, 2023-2033 (US$ billion)
Figure 38 Rare Diseases Market Share Forecast by Type, 2023, 2028, 2033 (%)
Figure 39 Non-biologics Market Forecast by Region, 2023-2033 (US$ billion)
Figure 40 Non-biologics Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Biologics Market Forecast by Region, 2023-2033 (US$ billion)
Figure 42 Biologics Market Share Forecast by Region, 2023 & 2033 (%)
Figure 43 Rare Diseases Market Attractiveness Index by End-users
Figure 44 Rare Diseases Market Forecast by End-users, 2023-2033 (US$ billion)
Figure 45 Rare Diseases Market Share Forecast by End-users, 2023, 2028, 2033 (%)
Figure 46 Specialty Pharmacies Market Forecast by Region, 2023-2033 (US$ billion)
Figure 47 Specialty Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 48 Hospital Pharmacies Market Forecast by Region, 2023-2033 (US$ billion)
Figure 49 Hospital Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 50 Retail Pharmacies Market Forecast by Region, 2023-2033 (US$ billion)
Figure 51 Retail Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 52 Rare Diseases Market Attractiveness Index by Age
Figure 53 Rare Diseases Market Forecast by Age, 2023-2033 (US$ billion)
Figure 54 Rare Diseases Market Share Forecast by Age, 2023, 2028, 2033 (%)
Figure 55 Adult Market Forecast by Region, 2023-2033 (US$ billion)
Figure 56 Adult Market Share Forecast by Region, 2023 & 2033 (%)
Figure 57 Pediatric Market Forecast by Region, 2023-2033 (US$ billion)
Figure 58 Pediatric Market Share Forecast by Region, 2023 & 2033 (%)
Figure 59 Rare Diseases Market Forecast by Region 2023, 2028, 2033 (Revenue, CAGR%)
Figure 60 Rare Diseases Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 61 Rare Diseases Market by Region, 2023-2033 (US$ bn)
Figure 62 North America Rare Diseases Market Attractiveness Index
Figure 63 North America Rare Diseases Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 64 North America Rare Diseases Market Forecast by Country, 2023-2033 (US$ billion)
Figure 65 North America Rare Diseases Market Share Forecast by Country, 2023 & 2033 (%)
Figure 66 North America Rare Diseases Market Forecast by Diseases, 2023-2033 (US$ billion)
Figure 67 North America Rare Diseases Market Share Forecast by Diseases, 2023 & 2033 (%)
Figure 68 North America Rare Diseases Market Forecast by Type, 2023-2033 (US$ billion)
Figure 69 North America Rare Diseases Market Share Forecast by Type, 2023 & 2033 (%)
Figure 70 North America Rare Diseases Market Forecast by End-users, 2023-2033 (US$ billion)
Figure 71 North America Rare Diseases Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 72 North America Rare Diseases Market Forecast by Age, 2023-2033 (US$ billion)
Figure 73 North America Rare Diseases Market Share Forecast by Age, 2023 & 2033 (%)
Figure 74 U.S. Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 75 Canada Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 76 Europe Rare Diseases Market Attractiveness Index
Figure 77 Europe Rare Diseases Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 78 Europe Rare Diseases Market Forecast by Country, 2023-2033 (US$ billion)
Figure 79 Europe Rare Diseases Market Share Forecast by Country, 2023 & 2033 (%)
Figure 80 Europe Rare Diseases Market Forecast by Diseases, 2023-2033 (US$ billion)
Figure 81 Europe Rare Diseases Market Share Forecast by Diseases, 2023 & 2033 (%)
Figure 82 Europe Rare Diseases Market Forecast by Type, 2023-2033 (US$ billion)
Figure 83 Europe Rare Diseases Market Share Forecast by Type, 2023 & 2033 (%)
Figure 84 Europe Rare Diseases Market Forecast by End-users, 2023-2033 (US$ billion)
Figure 85 Europe Rare Diseases Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 86 Europe Rare Diseases Market Forecast by Age, 2023-2033 (US$ billion)
Figure 87 Europe Rare Diseases Market Share Forecast by Age, 2023 & 2033 (%)
Figure 88 Germany Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 89 UK Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 90 France Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 91 Italy Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 92 Spain Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 93 Russia Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 94 Rest of Europe Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 95 Asia Pacific Rare Diseases Market Attractiveness Index
Figure 96 Asia Pacific Rare Diseases Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 97 Asia Pacific Rare Diseases Market Forecast by Country, 2023-2033 (US$ billion)
Figure 98 Asia Pacific Rare Diseases Market Share Forecast by Country, 2023 & 2033 (%)
Figure 99 Asia Pacific Rare Diseases Market Forecast by Diseases, 2023-2033 (US$ billion)
Figure 100 Asia Pacific Rare Diseases Market Share Forecast by Diseases, 2023 & 2033 (%)
Figure 101 Asia Pacific Rare Diseases Market Forecast by Type, 2023-2033 (US$ billion)
Figure 102 Asia Pacific Rare Diseases Market Share Forecast by Type, 2023 & 2033 (%)
Figure 103 Asia Pacific Rare Diseases Market Forecast by End-users, 2023-2033 (US$ billion)
Figure 104 Asia Pacific Rare Diseases Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 105 Asia Pacific Rare Diseases Market Forecast by Age, 2023-2033 (US$ billion)
Figure 106 Asia Pacific Rare Diseases Market Share Forecast by Age, 2023 & 2033 (%)
Figure 107 Japan Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 108 China Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 109 India Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 110 Australia Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 111 South Korea Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 112 Rest of Asia Pacific Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 113 Latin America Rare Diseases Market Attractiveness Index
Figure 114 Latin America Rare Diseases Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 115 Latin America Rare Diseases Market Forecast by Country, 2023-2033 (US$ billion)
Figure 116 Latin America Rare Diseases Market Share Forecast by Country, 2023 & 2033 (%)
Figure 117 Latin America Rare Diseases Market Forecast by Diseases, 2023-2033 (US$ billion)
Figure 118 Latin America Rare Diseases Market Share Forecast by Diseases, 2023 & 2033 (%)
Figure 119 Latin America Rare Diseases Market Forecast by Type, 2023-2033 (US$ billion)
Figure 120 Latin America Rare Diseases Market Share Forecast by Type, 2023 & 2033 (%)
Figure 121 Latin America Rare Diseases Market Forecast by End-users, 2023-2033 (US$ billion)
Figure 122 Latin America Rare Diseases Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 123 Latin America Rare Diseases Market Forecast by Age, 2023-2033 (US$ billion)
Figure 124 Latin America Rare Diseases Market Share Forecast by Age, 2023 & 2033 (%)
Figure 125 Brazil Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 126 Mexico Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 127 Rest of Latin America Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 128 MEA Rare Diseases Market Attractiveness Index
Figure 129 MEA Rare Diseases Market by Region, 2023, 2028 & 2033 (US$ billion)
Figure 130 MEA Rare Diseases Market Forecast by Country, 2023-2033 (US$ billion)
Figure 131 MEA Rare Diseases Market Share Forecast by Country, 2023 & 2033 (%)
Figure 132 MEA Rare Diseases Market Forecast by Diseases, 2023-2033 (US$ billion)
Figure 133 MEA Rare Diseases Market Share Forecast by Diseases, 2023 & 2033 (%)
Figure 134 MEA Rare Diseases Market Forecast by Type, 2023-2033 (US$ billion)
Figure 135 MEA Rare Diseases Market Share Forecast by Type, 2023 & 2033 (%)
Figure 136 MEA Rare Diseases Market Forecast by End-users, 2023-2033 (US$ billion)
Figure 137 MEA Rare Diseases Market Share Forecast by End-users, 2023 & 2033 (%)
Figure 138 MEA Rare Diseases Market Forecast by Age, 2023-2033 (US$ billion)
Figure 139 MEA Rare Diseases Market Share Forecast by Age, 2023 & 2033 (%)
Figure 140 GCC Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 141 South Africa Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 142 Rest of MEA Rare Diseases Market Forecast, 2023-2033 (US$ billion, AGR %)
Figure 143 AbbVie Inc.: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 144 AbbVie Inc.: Regional Market Shares (%), 2021
Figure 145 AbbVie Inc.: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 146 AbbVie Inc.: R&D, 2015-2022 (US$ million, AGR%)
Figure 147 Amgen Inc.: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 148 Amgen Inc.: Regional Market Shares (%), 2022
Figure 149 Amgen Inc.: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 150 Amgen Inc.: R&D, 2015-2022 (US$ million, AGR%)
Figure 151 Biogen Inc.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 152 Biogen Inc.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 153 Biogen Inc.: R&D, 2015-2021 (US$ million, AGR%)
Figure 154 F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 155 F. Hoffmann-La Roche Ltd.: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 156 F. Hoffmann-La Roche Ltd.: R&D, 2015-2021 (US$ million, AGR%)
Figure 157 Johnson & Johnson Services, Inc.: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 158 Johnson & Johnson Services, Inc.: Regional Market Shares (%), 2021
Figure 159 Johnson & Johnson Services, Inc.: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 160 Johnson & Johnson Services, Inc.: R&D, 2015-2022 (US$ million, AGR%)
Figure 161 Merck & Co Inc.: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 162 Merck & Co Inc.: Regional Market Shares (%), 2021
Figure 163 Merck & Co Inc.: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 164 Merck & Co Inc.: R&D, 2015-2022 (US$ million, AGR%)
Figure 165 Novartis AG: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 166 Novartis AG: Regional Market Shares (%), 2021
Figure 167 Novartis AG: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 168 Novartis AG: R&D, 2015-2022 (US$ million, AGR%)
Figure 169 Pfizer Inc.: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 170 Pfizer Inc.: Regional Market Shares (%), 2021
Figure 171 Pfizer Inc.: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 172 Pfizer Inc.: R&D, 2015-2022 (US$ million, AGR%)
Figure 173 Sanofi S.A.: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 174 Sanofi S.A.: Regional Market Shares (%), 2021
Figure 175 Sanofi S.A.: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 176 Sanofi S.A.: R&D, 2015-2022 (US$ million, AGR%)
Figure 177 Takeda Pharmaceuticals: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 178 Takeda Pharmaceuticals: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 179 Takeda Pharmaceuticals: R&D, 2015-2022 (US$ million, AGR%)
Figure 180 Teva Pharmaceuticals: Net Revenue, 2015-2021 (US$ million, AGR%)
Figure 181 Teva Pharmaceuticals: Regional Market Shares (%), 2021
Figure 182 Teva Pharmaceuticals: Gross Profit, 2015-2021 (US$ million, AGR%)
Figure 183 Teva Pharmaceuticals: R&D, 2015-2021 (US$ million, AGR%)
Figure 184 Bristol-Myers Squibb Company: Net Revenue, 2015-2022 (US$ million, AGR%)
Figure 185 Bristol-Myers Squibb Company: Gross Profit, 2015-2022 (US$ million, AGR%)
Figure 186 Bristol-Myers Squibb Company: R&D, 2015-2022 (US$ million, AGR%)
